Evaluation of gemcitabine and carboplatin dosing in patients with cisplatin-ineligible metastatic urothelial carcinoma

Eleni Gamvroulas,Erin Bailey,Erik Harrington,Emma Jones,Rebecca Martin,Benjamin L. Maughan
DOI: https://doi.org/10.1016/j.clgc.2024.102279
IF: 3.121
2024-11-30
Clinical Genitourinary Cancer
Abstract:Background The National Comprehensive Cancer Network Bladder Cancer Guidelines recommend carboplatin and gemcitabine as first-line treatment in patients with cisplatin-ineligible, metastatic urothelial cancer (mUC) as a Category 1 recommendation. For these patients, the median overall survival is 9.3 months. Carboplatin is purported to offer a more tolerable side-effect profile; however, many patients still require dose-reductions, dose-delays, and hospitalizations. Given the inability for mUC patients to tolerate this palliative regimen, we aim to determine whether initiating therapy with a lower dose regimen is justified. Methods A single-institution retrospective analysis was conducted to review eligible patients treated with carboplatin plus gemcitabine between May 1, 2014, and October 31, 2022. Data was collected via manual chart review to include information regarding patient baseline characteristics, chemotherapy doses, reductions, delays, toxicities, and effectiveness. Results Forty-three patients met inclusion criteria. Nineteen patients (44%) required ≥ 1 dose reduction during therapy. Twenty-six patients (60%) started with a full-dose regimen, and 14 (54%) of those patients required a dose reduction during treatment. Seventeen patients (40%) started with a reduced-dose regimen, and 5 (29%) of those patients required a dose reduction during treatment. No patients received 6 cycles at full dose, and 6 patients (14%) received the anticipated 6 cycles with dose reductions. One patient (2%) was able to tolerate >80% relative dose intensity of both carboplatin and gemcitabine. Conclusions Cisplatin-ineligible mUC patients were unable to tolerate full-dose carboplatin and gemcitabine. As this is a palliative regimen, it would be pertinent to consider starting therapy at a reduced dose to minimize treatment interruptions, dose omissions and side effects.Micro-abstract: Per the NCCN Guidelines, first-line therapy for patients with cisplatin-ineligible, metastatic urothelial cancer is gemcitabine and carboplatin. This therapy is recognized as being more tolerable and having fewer side effects than gemcitabine and cisplatin. As carboplatin is a platinum agent, it assuredly still has side effects that may impact tolerability. This single-center retrospective review evaluated dosing and toxicities in gemcitabine and carboplatin therapy in this patient population to assess safety and tolerability. Findings indicate that there are significant toxicities which warranted dose adjustments, addition of granulocyte colony stimulating factor, and frequent visits to the hospital. As this therapy is used in the palliative setting, it warrants consideration of dosing adjustments at the outset to decrease these toxicities.
oncology,urology & nephrology
What problem does this paper attempt to address?